Non-Detection of Human Herpesvirus 8 (HHV-8) DNA in HHV-8-Seropositive Blood Donors from Three Brazilian Regions by Levi, José Eduardo et al.
Non-Detection of Human Herpesvirus 8 (HHV-8) DNA in
HHV-8-Seropositive Blood Donors from Three Brazilian
Regions
Jose ´ Eduardo Levi
1, Maria Claudia Nascimento
1,3, Laura Masami Sumita
1, Vanda Akico Ueda Fick de
Souza
1,2, Wilton S. Freire
1, Philippe Mayaud
3, Claudio S. Pannuti
1,2*
1Instituto de Medicina Tropical da Universidade de Sa ˜o Paulo, Sa ˜o Paulo, Brazil, 2Departamento de Mole ´stias Infecciosas e Parasita ´rias (LIM 52 -HC), Faculdade de
Medicina da Universidade de Sa ˜o Paulo, Sa ˜o Paulo, Brazil, 3Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United
Kingdom
Abstract
Human herpesvirus 8 (HHV-8), also known as Kaposi’s sarcoma-associated herpesvirus (KSHV), is the etiologic agent of all
forms of Kaposi’s sarcoma, primary effusion lymphoma and the plasmablastic cell variant of multicentric Castleman disease.
In endemic areas of sub-Saharan Africa, blood transfusions have been associated with a substantial risk of HHV-8
transmission. By contrast, several studies among healthy blood donors from North America have failed to detect HHV-8 DNA
in samples of seropositive individuals. In this study, using a real-time PCR assay, we investigated the presence of HHV-8 DNA
in whole-blood samples of 803 HHV-8 blood donors from three Brazilian states (Sa ˜o Paulo, Amazon, Bahia) who tested
positive for HHV-8 antibodies, in a previous multicenter study. HHV-8 DNA was not detected in any sample. Our findings do
not support the introduction of routine HHV-8 screening among healthy blood donors in Brazil. (WC=140).
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Introduction
Human herpesvirus 8 (HHV-8), also known as Kaposi’s
sarcoma-associated herpesvirus (KSHV), is the etiologic agent of
all forms of Kaposi’s sarcoma, primary effusion lymphoma and the
plasmablastic cell variant of multicentric Castleman disease [1].
Detection of HHV-8 antibodies has been extensively used to
determine the prevalence of the infection and to investigate routes
of viral transmission. Initial studies have suffered from a wide
variability of serological assays. Nevertheless, they uncovered the
existence of different rates of HHV-8 worldwide. As expected, the
highest prevalence rates were observed in areas where Kaposi’s
sarcoma (KS) was endemic, like in Eastern and Central Africa [2].
In these areas, seroprevalence in blood donors may be as high as
48%, as observed in Tanzania [3]. This contrasts with much lower
rates found in US blood donors ranging from 2.8% to 7.3% [4–6].
Brazil may be considered a region of intermediate endemicity, as
we have detected a HHV-8 seroprevalence of 25% among 3,493
blood donors from three different regions of the country [7].
Since HHV-8 has been causally linked to KS, concern was
raised earlier on its potential transmission by blood transfusion and
organ transplantation. Moreover, the detection of HHV-8 RNA in
target cells inoculated with filtered fluids collected from activated
CD19 cells of a healthy North American blood donor in 1997
fostered research on the possible transmission of this oncogenic
virus by blood transfusion [8], analogous to the proven association
between Human T-cell Lymphotropic Virus 1 (HTLV-1) and the
development of leukemia among recipients of infected blood units.
Since then, a number of studies have addressed this important
issue, with discordant results. In endemic areas of sub-Saharan
Africa, blood transfusions have been associated with a substantial
risk of HHV-8 transmission. For example, in Tanzania and
Central African Republic, HHV-8 DNA was detected in 4.5% and
22.5% of blood donors, respectively [3;9]. In Uganda, HHV-8
seropositivity was shown to be significantly more frequent in
transfused versus never-transfused children with sickle-cell disease
[10], and recipients of HHV-8 seropositive blood units were at a
significantly higher risk of seroconversion compared to recipients
of seronegative blood units [11]. By contrast, several studies
among healthy blood donors from North America using sensitive
PCR assays have failed to detect HHV-8 DNA in samples of
HHV-8 seropositive individuals [4;12;13]. A large cohort of
donor-recipient pairs in the US did not identify any case of HHV-
8 transmission [5], which was corroborated by findings of a similar
study in Jamaica [14].
In one Brazilian study, HHV-8 antibodies were detected in 16/
400 (4%) blood donors, one of whom was found to also harbor
HHV-8 DNA in both peripheral blood mononuclear cells
(PBMCs) and plasma [15]. So far, universal leukoreduction has
not been implemented in the country, providing theoretical
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associated viruses such as herpesviruses.
The aim of this study was to evaluate the prevalence of HHV-8
DNA in blood samples of apparently healthy HHV-8 seropositive
blood donors to determine their potential for HHV-8 transmission.
Materials and Methods
Study sites
Brazil has a population of 190 million inhabitants, mainly
composed of descendants of Caucasian, African and Amerindian
indigenous populations, with a large degree of ethnic mixing. The
majority of Caucasian descendants live in the Southern parts of the
country, African descendants are ubiquitous with a large presence
in the Northeast, whilst most indigenous Amerindian populations
live in remote areas of the Central-Western and Northern regions.
For this study, we included samples from the main governmental
state blood banks located in the widely-separated cities of Manaus
(Amazon state, North), Salvador (Bahia state, Northeast), and Sa ˜o
Paulo (Sa ˜o Paulo state, Southeast).
Study population, enrolment procedures and HHV-8
seropositive specimens
Frozen whole blood specimens were retrieved from a repository
of blood samples obtained from voluntary first time blood donors
who tested positive for HHV-8 antibodies using a whole cell
ELISA. Those specimens were collected during a multicenter
study conducted among blood donors from these three large urban
centers of Brazil, which aimed to determine the seroprevalence,
risk factors and molecular characterization of HHV-8 infection in
these regions of Brazil [7]. The characteristics of the study
population and enrolment procedures as well as a detailed
description of the ELISA assays used for HHV-8 serological
screening have been reported elsewhere [7,16]. As reported,
HHV-8 serum antibodies were detected by whole-virus ELISA in
878 of 3,493 (25%) screened blood donors.
Ethical considerations
Eligible blood donors who consented to the study were asked to
read an information sheet and sign a consent form giving
permission for their samples to be tested for HHV-8, in addition
to serological tests performed routinely in Brazilian blood banks,
and to provide an extra 10 mL of EDTA treated blood sample for
molecular studies on HHV-8.
The Institutional Review Boards of each blood bank (Research
Ethics Committees of the Fundac ¸a ˜o de Hematologia e Hemoter-
apia da Bahia-HEMOBA, the Fundac ¸a ˜o de Hematologia e
Hemoterapia do Amazonas (HEMOAm), and the Hospital das
Clı ´nicas da Faculdade de Medicina da Universidade de Sa ˜o Paulo
(HEMOSP)), as well as the Ethics Board of the Brazilian Ministry
of Health (CONEP) and the Research Ethics Committee of the
London School of Hygiene & Tropical Medicine approved the
study protocol.
HHV-8 molecular assays
DNA extraction. DNA was extracted from frozen EDTA-treated
whole blood (200 mL), using QIAmp DNA Blood Mini kit
(Qiagen, Brazil) and eluted into 100 mL of the elution buffer
provided in the kit. DNA concentration was measured in a subset
of 300 randomly chosen samples (100 from each center) by
spectrophotometry at 260 nM in the NanoDrop (Thermo
Scientific NanoDrop Products-USA) system. Values ranging
between 1 and 160 ng/mL (mean 40 ng/mL, SD 623,6 ng/mL;
median37 ng/mL), were verified, while three samples (1%) had no
OD values. The eluate volume input in the real-time PCR was
5 mL for all samples, resulting in a human DNA input in between
5 and 800 ng, corresponding roughly to 75 to 121,212 diploid cells
(mean 6,060 cells). DNA quality was evaluated by PCR
amplification of the human b-globin gene, prior to investigation
of HHV-8 DNA.
ORF 26 real-time PCR
Sensitivity. Analytical sensitivity of this assay was obtained
by using a plasmid containing an insert of 233 base pairs from the
minor capsid ORF26 cloned into pGEMT-easy vector (Promega-
2800 Woods Hollow Road Madison-USA). The designed primers
(Table 1) amplified a 66 bp fragment from the cloned amplicon.
The DNA concentration of a pure preparation of the plasmid was
determined by spectrophotometry to contain 68.47 mg/ml,
corresponding to 1.95610
13 copies/mL. This plasmid solution
was serially diluted on fresh human blood seronegative and PCR
negative for HHV-8, in order to obtain a dilution series of HHV-8
DNA from 1.95610
4 to 10
0 copies/mL of whole blood. Ten
replicates were extracted from each dilution point and submitted
to a real-time PCR reaction containing 400 gM of forward and
reverse primers and 160 gM of the probe (Table 1), in addition to
12.5 mL of 2X TaqMan Universal PCR Master Mix (Applied
Biosystems, Brazil) and 5 ml of the above described DNA eluate, in
a final volume of 25 mL.
Cycling conditions consisted of two initial heat-activation steps
of 50uC for 2 minutes (UNG) and 95uC for 10 minutes (Taq
polymerase), followed by 40 cycles of 15 seconds at 95uC and 1
minute at 65uC, in an ABI 7300 real-time PCR instrument. Probit
analysis was performed using the proportion of experimental
points displaying a positive result, i.e. Ct below the cut-off
automatically established by the real-time PCR instrument. The
concentration of 1,000 copies/mL was determined by this analysis
to present a hit rate of 95%, corresponding to a cycle threshold
(Ct) of 36 (Table 2).
Specificity. The assay was challenged against DNA from
CMV, HSV-1, HSV-2, EBV, VZV and HHV-6 derived from cell
lines and standards with no amplification.
Run control. DNA isolated from the cell line BCBL-1,
previously demonstrated to contain 36 copies of HHV-8 per cell
[17] was used as a positive run control on each experiment. A
blank (water) tube was included in each run as a negative control.
ORF 73 real time PCR
Real-time PCR for this target was performed under the same
conditions as above. Primers and probe were described by
Krishnan et al. [18]. A plasmid pGEX-5X containing an insert
from the ORF 73 (generous gift of Dr. Harutaka Katano,
Laboratory of Pathology, AIDS Research Center, National
Table 1. Primers and probe used in the TaqMan assay for
HHV-8 DNA.
Sequence 59 39
GenBank
position
a
Forward primer GGGCCCCGGATGATGTA 137
Reverse Primer GCCCCATAAATGACACATTGG 182
Probe 6- FAM-AGATCAAGTTCCGCCATAT –MGB 157
aAccording to Genbank entry: AF042371.1.
doi:10.1371/journal.pone.0023546.t001
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determine the limit of sensitivity, which was of 700 copies/mL
of whole blood at the 95% detection rate.
Results
b-globin could be amplified in 803 (91.5%) of the 878 ELISA-
positive samples, indicating adequate amounts of purified DNA
and removal of PCR inhibitors. HHV-8 DNA was not detected in
any of the valid 803 whole-blood samples after triplicate PCR
testing. In 48/803 (6%) of the samples, discrepancies were
observed among the replicates in the real-time PCR assay (one
positive in three), always at Ct values above the established
threshold of 36. Since this could represent donors harboring low
viral loads (,1,000 copies/mL), we repeated the analysis and also
submitted the DNA to amplification of another region (ORF73). A
positive amplification was never reproducible in the same assay
nor corroborated by the ORF73 real-time PCR assay for any of
these samples and the 48 donors were considered as HHV-8 DNA
negative.
Discussion
Almost 20 years after the discovery of HHV-8 by Chang et al.
[18] there is still no consensus about its potential transmission by
blood transfusion. In this study, despite testing a large number of
HHV-8 seropositive blood donors by a stringent protocol of repeat
and complementary PCRs, HHV-8 DNA could not be consis-
tently detected in any blood sample.
The decision to test blood donors shown to have HHV-8
antibodies after screening with a whole virus ELISA was
stimulated by a previous report from Uganda showing a
significantly higher risk of seroconversion among recipients of
HHV-8-seropositive blood units compared to recipients of HHV-8
seronegative blood [11]. The choice of appropriate serological
screening tests to detect HHV-8 infection, particularly in
apparently healthy individuals, is problematic due to the lack of
a gold-standard to ascertain the true status of infection. Routine
HHV-8 screening of blood donors is not currently performed
anywhere in the world. However, since HHV-8 transmission by
blood transfusion is biologically plausible, screening of blood units
might be considered in populations with intermediate to high
HHV-8 seroprevalence, especially when destined to be used for
immunocompromised recipients. In this case, recipients’ safety
would argue for the use of highly sensitive tests. The HHV-8
whole-virus ELISA used in this study, as well as other enzyme
immunoassays based on peptide-containing antigenic HHV-8
gene products, such as the lytic HHV-8 glycoprotein K8.1, have
been shown to have excellent sensitivity, making them suitable for
HHV-8 screening of blood donors [19;20].
The lack of detection of HHV-8 DNA in any of the 803 whole
blood samples from HHV-8 seropositive blood donors in the
present study corroborates findings of previous studies carried out
in low prevalence populations, but is in stark contrast with reports
from intermediate to high prevalence regions. In Italy, Bigoni et al.
[21] detected HHV-8 DNA in 5/56 (9%) PBMCs from blood
donors, while Brown et al. [22] detected HHV-8-DNA in 16.5% of
PBMCs from 158 HHV-8 seropositive healthy adults, and Vitale et
al. detected HHV-8 DNA in the PBMCs of one out of 12 healthy
HHV-8 seropositive individuals [23]. In Tanzania [3] and the
Central African Republic [9], HHV-8 DNA was detected in 4.5%
and 22.5% of blood donors, respectively. Conversely, our results
accord with studies undertaken among healthy blood donors from
low prevalence areas such as the USA. Hudnall et al. [4] evaluated
23 buffy-coat samples from HHV-8 seropositive blood donors
using nested PCR with primers specific for the ORF26 minor
capsid gene and the HHV-8 ORF72 v-cyclin gene, but did not
detect HHV-8 DNA in any sample. The same group tested 100
whole blood samples using a real-time PCR assay with TaqMan
probes and did not detect any HHV-8 DNA [13]. Pellet et al. [12],
performing nested PCR on whole blood samples from 138 donors
including 55 who were seropositive for HHV-8, also failed to
identify HHV-8 DNA in any sample. More recently, Qu et al. [6],
testing purified DNA equivalent to more than 3610
4 B-cells from
861 donors, including 40 samples from HHV-8 seropositive
individuals, did not detect HHV-8 DNA in any of these samples.
Furthermore, HHV-8 genomes were not detected from induced/
cultured PBMCs and CD19+ B-cells from 164 blood donors,
including seven HHV-8 seropositive samples [24]. Unfortunately,
in our work, we could not isolate PBMCs from whole blood
samples, as repository samples were immediately frozen after
whole blood collection at the blood bank. This could have helped
concentrate DNA and increased assay sensitivity. Moreover, the
freezing process may have led to some specimen damage, since in
9% of our samples we failed to amplify b-globin. Such sample
inadequacy rate is not uncommon when working with frozen
samples. However, DNA concentration was measured in a subset
of 300 randomly chosen samples and only three samples (1%) had
no OD values, indicating that the complete lack of HHV-8 DNA
detection could not be entirely attributed to these technical
limitations.
The consistent lack of HHV-8 DNA detection in blood donors
from countries with low HHV-8 seroprevalence might be
explained by the low number of seropositive donors enrolled in
such investigations. However, even when only seropositive healthy
individuals have been considered, striking differences between
non-endemic and endemic regions have persisted. One possible
hypothesis would be that, in endemic regions where there is an
active viral circulation, acute infections with lytic viral replication
and higher viral DNA copy numbers in the blood may not be
uncommon. Conversely, in non-endemic countries, healthy
immunocompetent HHV-8-seropositive individuals may harbor
predominantly HHV-8 latently-infected cells that would not
undergo productive (lytic) replication, unless in response to specific
triggers. However, even when both lytic replication and latency
occur concomitantly, such as demonstrated in HHV-8 seropositive
individuals co-infected with HIV, HHV-8 viral loads may be low
and frequently below the threshold of detection [25]. A recent
Table 2. Results of replicate testing of whole blood spiked
with known amounts of plasmid containing HHV-8-ORF 26.
Plasmid copies/mL
Number of positive replicates/
Number of tested replicates
19500 10/10
1950 10/10
975 9/10
487.5 8/10
243.7 7/10
195 2/10
121.8 2/10
60.9 1/10
12 0/10
1.2 0/10
doi:10.1371/journal.pone.0023546.t002
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which enhanced the performance of a very sensitive quantitative
real-time PCR (detection limit 1-6 copies) by purifying C19+ B-
lymphocytes corroborated the notion that, in US blood donors,
the prevalence of HHV-8 genomes in the circulatory blood is
extremely low and generally undetectable [6]. However, we must
acknowledge that the PCR method described in this study has a
lower sensitivity when compared to nested PCR methods adopted
in other studies. The aforementioned studies using PBMCs from
healthy Italian volunteers were able to detect HHV-8 DNA
sequences in 9 to 16% of the samples using PCR methods with a
threshold of approximately 3 copies of HHV-8 DNA per 10
6 cells.
Our positivity cut-off was 1,000 copies/mL. If one considers that
leukocyte counts on healthy blood donors average 5 to 10610
6
cells/mL, our method would classify as ‘positive’ donors harboring
between 100 and 200 copies of HHV-8 DNA per 10
6 cells. Viral
loads of PBMCs from a control Italian group (HIV-seronegative
non-KS patients) were shown to range from 13 to 2,128 copies/
million cells [26]. Consequently, our study cannot entirely rule out
the possibility of donors harboring very low HHV-8 viremia.
Nevertheless, our findings may alleviate concerns over the need to
screen donors for HHV-8 in Brazil and do not support the
introduction of routine HHV-8 screening in Brazilian blood
banks, since, in the current context, HHV-8 represents a low-level
infectious disease threat to our blood supply [27].
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